NEW YORK (GenomeWeb) – Proteomics-based diagnostics firm Provista Diagnostics today announced the closing of a financing round bringing in $6 million.
Funding from the Series A-2 Preferred financing round came from existing investors exercising warrants from a previous financing round, the New York-based company said, adding that proceeds will be used for continued commercial development, prospective clinical trials, key management hires, and general corporate purposes.
Provista said that it has raised a total of $32.7 million since 2011. In March, it disclosed that it raised $3.9 million. It is unclear if the $6 million includes the earlier raise.
Provista develops blood-based tests for the diagnosis, prognosis, and monitoring of breast and gynecological cancer patients.